NCT06083311已完成不适用
A Randomised, Triple-blinded, Placebo-controlled, Parallel Group Pilot Study, to Assess the Effect of Probiotic on Functional Constipation and Gut Microbiology
The Archer-Daniels-Midland Company2 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2023年10月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 55
- 试验地点
- 2
- 主要终点
- Difference in change in Cleveland Clinic Constipation score (total) from baseline (V2) to study end (V3)
研究概览
简要总结
Investigate the effect of a probiotic (live bacteria) in individuals with functional constipation.
详细描述
This study aims to investigate the safety and efficacy of live bacteria on defecation parameters in individuals with Functional Constipation. The trial will be run in Germany and will recruit adult men and women meeting the ROME-IV criteria for functional constipation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
Triple Blind Study
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males (at least 30% of total number of subjects) and females ≥ 18 years and ≤65 years old
- •Body Mass Index (BMI) 18.5 - 30.0 kg/m2
- •Fulfilment of the Rome IV FC diagnostic criteria at V1 and V2
- •Self-reported average stool frequency of 3 or less bowel movements per week
- •Self-reported average stool consistency of type 1-4 on the Bristol Stool Form Scale
- •Cleveland Clinic Constipation Score > 8 at V1
- •Readiness not to use any treatment/supplementation for complaints related to constipation (e.g. prokinetics, laxatives, enemas) during the study; exception: glycerol suppository and if it provides no benefit, participants are allowed to take oral laxatives (see section 0)
- •Readiness and ability to comply with and perform the procedures requested by the protocol
- •If receiving proton pump inhibitors (PPI), anticipated to continue PPI therapy for the duration of the trial
- •Readiness not to have any change in habitual diet or exercise patterns over the study period
- •If sexually active, commitment to use contraception methods
- •negative pregnancy testing (beta human chorionic gonadotropin test in urine) at V1
- •Generally, in the opinion of investigator, healthy individuals (e.g. no heart failure, no malignancy) Participation is based upon written informed consent by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study.
排除标准
- •Clinically relevant (as per investigators judgement) self-reported chronic disease of the gastrointestinal tract (e.g. irritable bowel syndrome, Crohn's disease, ulcerative colitis, celiac disease, diverticulitis, malabsorption disorder), neurological, cardiovascular, endocrine/reproductive, renal, or other chronic diseases likely to affect gut motility
- •Prior abdominal surgery in the past 3 years (except for laparoscopic appendectomy and cholecystectomy and other minor laparoscopic surgeries, as per investigator judgement, that are allowed)
- •Ongoing regular use of products that (in the investigator's opinion) are known to cause constipation or change gastric motility (e.g. iron; opioids; sucralfate; 5-HT3 antagonists (e.g. ondansetron); antacids with magnesium, calcium, or aluminum; anticholinergic agents; calcium supplements; trycyclic antidepressants; systemic steroids)
- •Any subjects with use of PPI within the last 8 weeks prior to Visit 1 (exception: continuous use for ≥ 8 week before Visit 1 is allowed)
- •Post-menopausal women, defined as >12 months after the last menstrual bleeding and not using hormonal contraception
- •Women ≥ 50 years using hormonal contraception
- •ALARM features in the past 3 months prior to study (e.g. fever, unintentional weight loss ≥5 kg, blood in stool, vomiting) and moderate or severe anorectal problems (e.g. rectal bleeding, pelvic organ prolapse, anal fissures)
- •Previously diagnosed lactose intolerance, gluten intolerance, cow's milk allergy and/or soya-allergy
- •Known allergy or hypersensitivity to any ingredients of the investigational product
- •Consumption of biotic supplements (probiotics, prebiotics, synbiotics or post-biotics) within 2 weeks prior to Visit 1 and during the study
- •Regular consumption of fibre supplements and/or laxatives more than 1x a week
- •Use of laxatives within 48 hrs prior to Visit 1
- •Use of antibiotic within 4 weeks prior to Visit 1 and during the study
- •Ongoing alcohol, drug, or medication abuse
- •Participation in other clinical trials within 4 weeks prior to Visit 1 and during the study
- •Planning travel for >1 week during the study duration
- •Anticipated major changes in diet or exercise during the study
- •Pregnant or lactating or planned to become pregnant during the study period
- •Smoking > 5 cigarettes per week
- •An irregular diet, an abnormal sleep cycle, or other lifestyle abnormalities, as per investigator judgement
- •Individuals who, in the opinion of the investigator, are considered to be incompliant clinical attendees or unlikely for any reason to be able to complete the trial as required
- •Clinically relevant deviation of screening laboratory parameters at V1
结局指标
主要结局
Difference in change in Cleveland Clinic Constipation score (total) from baseline (V2) to study end (V3)
时间窗: Baseline (V2), Day 28 (V3)
Difference in change in Cleveland Clinic Constipation score (CCCS) (total) from baseline (V2) to study end (V3) between verum and placebo groups. Higher scores in the CCCS indicate worse constipation symptoms. (Max score: 30)
次要结局
- Difference in change in total reflux symptoms score at 2 weeks after V2, compared to V2(Baseline (V2), Day 14)
- Difference in proportion of stools in different Bristol Stool Form Scale categories (1-2, 3-4, 5-7) at 1, 2, 3 week(s) after V2 and at V3, each compared to V2(Baseline (V2), Day 7, Day 14, Day 21 and Day 28)
- Difference in change in mean weekly number of spontaneous bowel movements (without assistance/ medication) at 1, 2, 3 week(s) after V2 and at V3, each compared to V2(Baseline (V2), Day 7, Day 14, Day 21 and Day 28)
- Difference in short chain fatty acids (SCFA) in stool samples collected prior to V2 and prior to V3(Baseline (V2), Day 28 (V3))
- Difference in findings of microbiome assessment using metagenomics techniques of stool samples collected prior to V2 and prior to V3(Baseline (V2), Day 28 (V3))
- Assessment of benefit by subject and investigator at V3 (4 point categorical scale)(Day 28 (V3))
- Difference in change in Cleveland Clinic Constipation score (total) at 2 week(s) after V2, compared to V2(Baseline (V2), Day 14)
- Difference in change in Patient Assessment of Constipation - Quality of Life score (total) from V2 to V3(Baseline (V2), Day 28 (V3))
- Difference in change in total reflux symptoms score from V2 to V3(Baseline (V2), Day 28 (V3))
- Difference in change in reflux symptoms sub-scale score (i.e. individual items) from V2 to V3(Baseline (V2), Day 28 (V3))
- Difference in change in Patient Assessment of Constipation - Quality of Life score (total) at 2 week(s) after V2, compared to V2(Baseline (V2), Day 14)
- Difference in change in Patient Assessment of Constipation - Quality of Life domain scores at 2 week(s) after V2, compared to V2(Baseline (V2), Day 14)
- Difference in Patient Assessment of Constipation - Quality of Life domain score from V2 to V3(Baseline (V2), Day 28 (V3))
- Difference in the weekly self-assessment of complete bowel emptying at 1, 2, 3 week(s) after V2 and at V3, each compared to V2(Baseline (V2), Day 7, Day 14, Day 21 and Day 28)
- Difference in change in reflux symptoms sub-scale score (i.e. individual items) at 2 weeks after V2, compared to V2(Baseline (V2), Day 14)
- Difference in change in mean weekly stool frequency at 1, 2, 3 week(s) after V2 and at V3, each compared to V2(Baseline (V2), Day 7, Day 14, Day 21 and Day 28)
- Difference in change of the weekly degree of straining (VAS) at 1, 2, 3 week(s) after V2 and at V3, each compared to V2(Baseline (V2), Day 7, Day 14, Day 21 and Day 28)
- Difference in findings of targeted metabolomic analysis of stool samples collected prior to V2 and prior to V3(Baseline (V2), Day 28 (V3))
- Difference in change of the weekly defecation/ rectal pain (VAS) at 1, 2, 3 week(s) after V2 and at V3, each compared to V2(Baseline (V2), Day 7, Day 14, Day 21 and Day 28)
- Difference in weekly need for digital assistance at 1, 2, 3 week(s) after V2 and at V3, each compared to V2(Baseline (V2), Day 7, Day 14, Day 21 and Day 28)
- Percentage of subjects with matching records of blinded assessment concern-ing the IP type they received (verum, placebo) and the actual IP assignment(Day 28 (V3))
- Assessment of the number of adverse events between the intervention and placebo(Day 28 (V3))
- Difference in weekly average use of laxatives at 1, 2, 3 week(s) after V2 and at V3, each compared to V2(Baseline (V2), Day 7, Day 14, Day 21 and Day 28)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Effects of Probiotics Supplementation on Intestinal Microbiome in Malignancy Pts(Get Pelvic/Abdominal Rtx)CancerNCT01706393Seoul National University Hospital26
已完成
3 期
Probiotics-prebiotic Fiber Therapy in Parkinson's Disease Patients With ConstipationParkinson DiseaseConstipationNCT04451096National University of Malaysia48
已完成
不适用
Probiotic Intervention for Gut FunctionGut FunctionNCT05155449Probi AB200
已完成
不适用
Probiotic Intervention for Occasional ConstipationGut FunctionOccasional ConstipationNCT06444139Probi AB100
已完成
不适用
The Effect of Probiotic Intake on Intestinal Permeability in Healthy AdultsIntestinal Barrier FunctionNCT03611400University of Florida39